Team:Imperial College London

From 2009.igem.org

(Difference between revisions)
(Abstract)
Line 3: Line 3:
<br><br>
<br><br>
=Abstract=
=Abstract=
-
For iGEM 2009, the Imperial College London team is proud to present <i>The E.ncapsulator</i>. We propose a versatile manufacture and delivery platform by which therapeutics can be reliably targeted to the intestine. <i>The E.ncapsulator</i> represents a novel approach to drug delivery that bypasses the need for expensive purification, packaging and storage treatments.  
+
For iGEM 2009 the Imperial College London team present to you <i>The E.ncapsulator</i>:  A versatile manufacture and delivery platform by which therapeutics can be reliably targeted to the gut.
-
Through the addition and modification of genetic pathways, our <i>E.coli</i> chassis progresses through a series of defined stages culminating in the production of a safe, inanimate pill. This sequential process involves drug production, protective encapsulation and genome deletion. The transition through each of these stages has been designed with industrial production in mind, using induction by both media and temperature.
+
Our E.coli chassis progresses through a series of defined stages culminating in the production of a safe, inanimate pill. This sequential process involves drug production, self-encapsulation in a protective coating and genome deletion. The temporal transition through each of these stages has been industrially optimised by both media and temperature.
-
<i>The E.ncapsulator</i>’s versatility is demonstrated by its ability to deliver any biologically synthesisable compound. The advantages that <i>The E.ncapsulator</i> offers over conventional pill manufacture makes it an attractive candidate for commercial development and additionally demonstrates the huge potential of synthetic biology in the field of manufacturing.
+
The <i>E.ncapsulator</i> provides a chassis to deliver any biologically synthesisable compound and bypasses the need for expensive purification, packaging and storage treatments. This makes it an attractive candidate for commercial pill development and demonstrates the huge potential of synthetic biology in the sphere of manufacturing.
<br>
<br>
<br>
<br>

Revision as of 12:04, 17 September 2009

The E.ncapsulator



Abstract

For iGEM 2009 the Imperial College London team present to you The E.ncapsulator: A versatile manufacture and delivery platform by which therapeutics can be reliably targeted to the gut.

Our E.coli chassis progresses through a series of defined stages culminating in the production of a safe, inanimate pill. This sequential process involves drug production, self-encapsulation in a protective coating and genome deletion. The temporal transition through each of these stages has been industrially optimised by both media and temperature.

The E.ncapsulator provides a chassis to deliver any biologically synthesisable compound and bypasses the need for expensive purification, packaging and storage treatments. This makes it an attractive candidate for commercial pill development and demonstrates the huge potential of synthetic biology in the sphere of manufacturing.


To find out more about our project, and to learn about each module, click below:

Forward arrow.jpg



Project overview



Mr. Gene   Geneart   Clontech   Giant Microbes